CAR-T Therapy in patients 75+ with Relapsed/Refractory DLBCL | Pierre Bories, MD, PhD | EHA 2024

Dr. Pierre Bories presents a study looking at CD-19 CAR-T therapy for Diffuse Large B-Cell Lymphoma patients who are over the age of 75. This study looks at the efficacy and side effects of DLBCL patients over 75 receiving this treatment.
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtre...
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree...